Payment overview · 2025
General Payments
$532.20
24 reported records · 11 companies
Healthcare provider profile · identity verified
Robert R Perry, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARKER HEIGHTS, TX · NPI 1841272481
Verified facts
What the public records show
CMS Open Payments records show Robert R Perry, MD received $532.20 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.26 | 26.2% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $89.48 | 16.8% | 4 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $65.61 | 12.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $45.02 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.23 | 8.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.82 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.27 | 6.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.36 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.16 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.91 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.08 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $532.20 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.84 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $89.48 | 4 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $65.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 92 |
| Lisinopril | Lisinopril | 249 | 83 |
| Losartan Potassium | Losartan Potassium | 223 | 77 |
| Metformin Hcl | Metformin Hcl | 220 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 72 |
| Gabapentin | Gabapentin | 204 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 56 |
| Furosemide | Furosemide | 149 | 56 |
| Trazodone Hcl | Trazodone Hcl | 143 | 48 |
| Omeprazole | Omeprazole | 130 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 47 |
| Alprazolam | Alprazolam | 125 | 22 |
| Ozempic | Semaglutide | 119 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 40 |
| Carvedilol | Carvedilol | 104 | 36 |
| Montelukast Sodium | Montelukast Sodium | 102 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 29 |
| Clonazepam | Clonazepam | 95 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 20 |
| Methocarbamol | Methocarbamol | 85 | 41 |
| Potassium Chloride | Potassium Chloride | 84 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 20 |
| Simvastatin | Simvastatin | 80 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 25 |
| Tramadol Hcl | Tramadol Hcl | 75 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 23 |
| Glipizide Er | Glipizide | 73 | 21 |
| Ondansetron Odt | Ondansetron | 67 | 15 |
| Ibuprofen | Ibuprofen | 65 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 63 | 17 |
| Dexamethasone | Dexamethasone | 63 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 20 |
| Glipizide | Glipizide | 61 | 20 |
| Jardiance | Empagliflozin | 59 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 16 |
| Levofloxacin | Levofloxacin | 54 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 54 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Indomethacin | Indomethacin | 53 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Celecoxib | Celecoxib | 48 | 20 |
| Eliquis | Apixaban | 48 | 12 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Pregabalin | Pregabalin | 48 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 17 |
| Metformin Hcl Er | Metformin Hcl | 44 | 18 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 13 |
| Prednisone | Prednisone | 43 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Valacyclovir | Valacyclovir Hcl | 40 | 13 |
| Diazepam | Diazepam | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Spironolactone | Spironolactone | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | 14 |
| Meloxicam | Meloxicam | 35 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 13 |
| Azithromycin | Azithromycin | 27 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 18 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Famotidine | Famotidine | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $532.20 · 24 records | Novo Nordisk Inc | AIRSUPRA, APTIMA, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, INSPIRE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error